{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.18","value":"62.8"},{"groupId":"OG001","spread":"21.33","value":"60.7"},{"groupId":"OG002","spread":"21.82","value":"62.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"201"},{"groupId":"OG002","value":"200"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.44","value":"-2.4"},{"groupId":"OG001","spread":"16.27","value":"-4.3"},{"groupId":"OG002","spread":"15.60","value":"-3.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"138"},{"groupId":"OG001","value":"133"},{"groupId":"OG002","value":"120"}],"units":"Participants"}],"title":"Change at Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.06","value":"-1.6"},{"groupId":"OG001","spread":"18.46","value":"3.8"},{"groupId":"OG002","spread":"22.45","value":"-1.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"180"},{"groupId":"OG002","value":"123"}],"units":"Participants"}],"title":"Change at Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.86","value":"0.7"},{"groupId":"OG001","spread":"19.96","value":"3.5"},{"groupId":"OG002","spread":"24.07","value":"-0.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"142"},{"groupId":"OG002","value":"51"}],"units":"Participants"}],"title":"Change at Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.63","value":"0.2"},{"groupId":"OG001","spread":"22.17","value":"4.2"},{"groupId":"OG002","spread":"21.65","value":"1.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"105"},{"groupId":"OG002","value":"37"}],"units":"Participants"}],"title":"Change at Cycle 4 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.66","value":"-1.1"},{"groupId":"OG001","spread":"22.09","value":"4.3"},{"groupId":"OG002","spread":"22.06","value":"-2.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"81"},{"groupId":"OG002","value":"26"}],"units":"Participants"}],"title":"Change at Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.76","value":"-4.0"},{"groupId":"OG001","spread":"23.25","value":"5.6"},{"groupId":"OG002","spread":"19.43","value":"-4.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"13"}],"units":"Participants"}],"title":"Change at Cycle 6 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.01","value":"-2.5"},{"groupId":"OG001","spread":"21.77","value":"4.3"},{"groupId":"OG002","spread":"12.30","value":"1.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"50"},{"groupId":"OG002","value":"10"}],"units":"Participants"}],"title":"Change at Cycle 7 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.83","value":"-2.6"},{"groupId":"OG001","spread":"16.98","value":"4.2"},{"groupId":"OG002","spread":"27.64","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"title":"Change at Cycle 8 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.74","value":"-5.8"},{"groupId":"OG001","spread":"16.44","value":"-5.6"},{"groupId":"OG002","spread":"12.60","value":"-4.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"title":"Change at Cycle 9 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.90","value":"-3.3"},{"groupId":"OG001","spread":"16.97","value":"-2.8"},{"groupId":"OG002","spread":"20.83","value":"2.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"title":"Change at Cycle 10 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.38","value":"-5.2"},{"groupId":"OG001","spread":"15.31","value":"3.9"},{"comment":"Number analyzed is 1 so standard deviation (SD) is not available.","groupId":"OG002","spread":"NA","value":"33.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"title":"Change at Cycle 11 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.41","value":"0.0"},{"groupId":"OG001","spread":"13.77","value":"-4.6"},{"groupId":"OG002","spread":"53.03","value":"4.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"title":"Change at Cycle 12 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.41","value":"0.0"},{"groupId":"OG001","spread":"14.25","value":"-3.2"},{"comment":"Number analyzed is 1 so SD is not available.","groupId":"OG002","spread":"NA","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"title":"Change at Cycle 13 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.26","value":"-1.2"},{"groupId":"OG001","spread":"15.00","value":"-6.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Change at Cycle 14 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"33.63","value":"3.6"},{"groupId":"OG001","spread":"8.61","value":"2.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Change at Cycle 15 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"42.08","value":"-16.7"},{"groupId":"OG001","spread":"9.62","value":"-5.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Change at Cycle 16 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.97","value":"-27.8"},{"groupId":"OG001","spread":"12.73","value":"-2.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Change at Cycle 17 Day 1"},{"categories":[{"measurements":[{"comment":"Number analyzed is 1 so SD is not available.","groupId":"OG000","spread":"NA","value":"-16.7"},{"groupId":"OG001","spread":"8.33","value":"-8.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Change at Cycle 18 Day 1"},{"categories":[{"measurements":[{"comment":"Number analyzed is 1 so SD is not available.","groupId":"OG000","spread":"NA","value":"0.0"},{"groupId":"OG001","spread":"11.79","value":"-8.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Change at Cycle 19 Day 1"},{"categories":[{"measurements":[{"comment":"Number analyzed is 1 so SD is not available.","groupId":"OG000","spread":"NA","value":"-25"},{"comment":"Number analyzed is 1 so SD is not available.","groupId":"OG001","spread":"NA","value":"-8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Change at Cycle 20 Day 1"},{"categories":[{"measurements":[{"comment":"Number analyzed is 1 so SD is not available.","groupId":"OG000","spread":"NA","value":"0.0"},{"comment":"Number analyzed is 1 so SD is not available.","groupId":"OG001","spread":"NA","value":"-16.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Change at Cycle 21 Day 1"},{"categories":[{"measurements":[{"comment":"Number analyzed is 1 so SD is not available.","groupId":"OG001","spread":"NA","value":"-16.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Change at Cycle 22 Day 1"},{"categories":[{"measurements":[{"comment":"Number analyzed is 1 so SD is not available.","groupId":"OG001","spread":"NA","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Change at Cycle 23 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.66","value":"-14.1"},{"groupId":"OG001","spread":"21.61","value":"-13.1"},{"groupId":"OG002","spread":"27.04","value":"-15.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"79"}],"units":"Participants"}],"title":"Change at End of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.51","value":"-17.4"},{"groupId":"OG001","spread":"15.96","value":"-10.4"},{"groupId":"OG002","spread":"24.08","value":"-24.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"21"}],"units":"Participants"}],"title":"Change at 30 Day Follow Up"}],"denoms":[{"counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"220"},{"groupId":"OG002","value":"221"}],"units":"Participants"}],"description":"The EORTC QLQ-C30 questionnaire consisted of 30 questions generating 5 functional scores (physical, role, cognitive, emotional, \\& social); a global health (GH) status/global quality of life scale score; 3 symptom scale scores (fatigue, pain, \\& nausea \\& vomiting); \\& 6 standalone one-item scores that capture additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, \\& diarrhea) \\& perceived financial burden. All items were graded by severity experienced during previous week \\& used 4-point-scale (1: not at all, 2: a little, 3: quite a bit, 4: very much). The scores were converted to health-related quality of life (HRQoL) scale ranging from 0-100. Higher scores indicating higher response levels (i.e., higher functioning, higher symptom severity).","dispersionType":"Standard Deviation","groups":[{"description":"Encorafenib + binimetinib + cetuximab. Encorafenib: Orally, once daily. Binimetinib: Orally, twice daily. Cetuximab: Standard of care.","id":"OG000","title":"Phase 3: Triplet Arm"},{"description":"Encorafenib + cetuximab. Encorafenib: Orally, once daily. Cetuximab: Standard of care.","id":"OG001","title":"Phase 3:Doublet Arm"},{"description":"Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab. Cetuximab: Standard of care. Irinotecan: Standard of care. Folinic Acid: Standard of care. 5-Fluorouracil: Standard of care. Following protocol amendment, eligible participants could crossover to receive either triplet or doublet regimen.","id":"OG002","title":"Phase 3:Control Arm"}],"paramType":"MEAN","populationDescription":"The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 participants. Here, 'Number Analyzed' signifies number of participants evaluable for the specified timepoints. All participants reported under 'Overall Number of Participants Analyzed' contributed data to the table but may not have evaluable data for every row.","reportingStatus":"POSTED","timeFrame":"Baseline, Cycle(C)1 Day(D)1 , C2 D1, C3 D1, C4 D1, C5 D1, C6 D1, C7 D1, C8 D1, C9 D1, C10 D1, C11 D1, C12 D1, C13 D1, C14 D1, C15 D1, C16 D1, C17 D1, C18 D1, C19 D1, C20 D1, C21 D1, C22 D1, C23 D1, End of Treatment, 30 Day Follow Up(each cycle of 28 days)","title":"(Phase 3) Change From Baseline in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for Cancer Participants (QLQ-C30) Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet","type":"SECONDARY","unitOfMeasure":"Units on a scale"}